Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 10/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 6/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.33 |
| ▸ | KRAS | P01116 | 5/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25216773 | 1.00 | TRAP1 (0.38) | TRAP1HSP90B1SPRHSP90AA1KRAS | |
| SCHEMBL31335781 | 0.89 | TRAP1 (0.39) | TRAP1HSP90B1SPRHSP90AA1HSP90AB1 | |
| SCHEMBL30378186 | 0.87 | TRAP1 (0.36) | TRAP1HSP90B1SPRHSP90AA1KRAS | |
| SCHEMBL25267660 | 0.87 | TRAP1 (0.36) | TRAP1HSP90B1SPRHSP90AA1KRAS | |
| SCHEMBL31335618 | 0.85 | SPR (0.39) | TRAP1HSP90B1SPRHSP90AA1KRAS | |
| SCHEMBL31335751 | 0.85 | TRAP1 (0.40) | TRAP1HSP90B1SPRKRAS | |
| SCHEMBL31335962 | 0.83 | TRAP1 (0.41) | TRAP1HSP90B1SPRHSP90AA1HSP90AB1 | |
| SCHEMBL31335695 | 0.80 | TRAP1 (0.40) | TRAP1HSP90B1SPRKRAS | |
| SCHEMBL31335555 | 0.80 | SPR (0.39) | TRAP1HSP90B1SPRHSP90AA1HSP90AB1 | |
| SCHEMBL31335788 | 0.80 | TRAP1 (0.48) | TRAP1HSP90B1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | claimed |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | TRAP1 1557/4885HSP90B1 2082/4885SPR 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.